ProPhase Labs, Inc. – NASDAQ:PRPH
ProPhase Labs stock price today
$0.315
-0.32
-50.55%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
ProPhase Labs stock price monthly change
-80.70%
month
ProPhase Labs stock price quarterly change
-80.70%
quarter
ProPhase Labs stock price yearly change
-86.24%
year
ProPhase Labs key metrics
Market Cap | 15.21M |
Enterprise value | 150.20M |
P/E | 21.78 |
EV/Sales | 1.59 |
EV/EBITDA | 11.19 |
Price/Sales | 1.54 |
Price/Book | 2.36 |
PEG ratio | N/A |
EPS | -1.32 |
Revenue | 28.71M |
EBITDA | -23.66M |
Income | -23.59M |
Revenue Q/Q | -81.17% |
Revenue Y/Y | -69.58% |
Profit margin | 6.91% |
Oper. margin | 8.82% |
Gross margin | 55.6% |
EBIT margin | 8.82% |
EBITDA margin | -82.42% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProPhase Labs stock price history
ProPhase Labs stock forecast
ProPhase Labs financial statements
| Jun 2023 | 13.21M | -3.44M | -26.03% |
|---|---|---|---|
| Sep 2023 | 8.36M | -5.14M | -61.46% |
| Dec 2023 | 3.49M | -8.75M | -250.1% |
| Mar 2024 | 3.63M | -6.26M | -172.4% |
| Mar 2024 | 3.63M | -6.26M | -172.4% |
|---|---|---|---|
| Sep 2025 | 35.64M | 2.16M | 6.08% |
| Oct 2025 | 35.64M | 2.16M | 6.08% |
| Dec 2025 | 38.18M | 2.52M | 6.62% |
Analysts Price target
Financials & Ratios estimates
| 2023-05-11 | 0.03 | 0.03 |
|---|
3.53%
Yield TTM
| Payout ratio | 72.19% |
|---|
| 2019 | 25.56% |
|---|---|
| 2020 | |
| 2021 | 4.18% |
| 2022 | 6.13% |
| 2023 |
| Jun 2023 | 91058000 | 31.80M | 34.92% |
|---|---|---|---|
| Sep 2023 | 91710000 | 35.28M | 38.47% |
| Dec 2023 | 91927000 | 42.54M | 46.28% |
| Mar 2024 | 90032000 | 45.16M | 50.17% |
| Jun 2023 | -6.95M | 1.21M | -47K |
|---|---|---|---|
| Sep 2023 | -4.65M | 332K | 1.2M |
| Dec 2023 | -213K | -1.26M | 2.92M |
| Mar 2024 | -5.11M | 2.43M | 2.27M |
ProPhase Labs alternative data
| Aug 2023 | 129 |
|---|---|
| Sep 2023 | 129 |
| Oct 2023 | 129 |
| Nov 2023 | 129 |
| Dec 2023 | 129 |
| Jan 2024 | 129 |
| Feb 2024 | 129 |
| Mar 2024 | 129 |
| Apr 2024 | 129 |
| May 2024 | 113 |
| Jun 2024 | 113 |
| Jul 2024 | 113 |
ProPhase Labs other data
6.94%
-93.06%
of PRPH is owned by hedge funds
21
-29
1.29M
-1.48M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2021 | 33943 | 0 |
| Mar 2022 | 1471 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KARKUS TED WILLIAM director, 10 perc.. | Option (right to buy) | 500,000 | $0.6 | $300,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Common Stock, par value $0.005 | 500,000 | $0.6 | $300,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Option (right to buy) | 600,000 | $0.6 | $360,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Common Stock, par value $0.005 | 600,000 | $0.6 | $360,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Option (right to buy) | 600,000 | $0.6 | $360,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Common Stock, par value $0.005 | 600,000 | $0.6 | $360,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Option (right to buy) | 600,000 | $0.6 | $360,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Common Stock, par value $0.005 | 600,000 | $0.6 | $360,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Option (right to buy) | 450,000 | $2 | $900,000 | ||
Option | KARKUS TED WILLIAM director, 10 perc.. | Common Stock, par value $0.005 | 450,000 | $2 | $900,000 |
| Patent |
|---|
Application Filling date: 16 Oct 2020 Issue date: 21 Apr 2022 |
Application Filling date: 19 Mar 2019 Issue date: 11 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Ted William Karkus (1959) Chairman & Chief Executive Officer | $445,000 |
| Ms. Monica Brady (1977) Chief Financial Officer | $213,080 |
ProPhase Labs: Lots Of Moving Pieces
Assertio Holdings: Acquiring Good Products Is The Key To Success
3 Small-Cap Pharma Stocks For A 2023 Melt-Up
ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
MDA Breakout Stocks Week 38 - September 2022: Short-Term Picks To Give You An Edge
ProPhase Labs: A Growth Stock At An Attractive Valuation
ProPhase Labs: Healthcare Done Right
Small And Microcap Newsletter: Athabasca Oil Continues To Strengthen Its Financial Position
As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
-
What's the price of ProPhase Labs stock today?
One share of ProPhase Labs stock can currently be purchased for approximately $0.32.
-
When is ProPhase Labs's next earnings date?
Unfortunately, ProPhase Labs's (PRPH) next earnings date is currently unknown.
-
Does ProPhase Labs pay dividends?
Yes, ProPhase Labs pays dividends and its trailing 12-month yield is 3.54% with 72% payout ratio. The last ProPhase Labs stock dividend of $0.3 was paid on 3 Jun 2021.
-
How much money does ProPhase Labs make?
ProPhase Labs has a market capitalization of 15.21M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 63.81% to 44.38M US dollars. ProPhase Labs made a loss 16.78M US dollars in net income (profit) last year or $0.03 on an earnings per share basis.
-
What is ProPhase Labs's stock symbol?
ProPhase Labs, Inc. is traded on the NASDAQ under the ticker symbol "PRPH".
-
What is ProPhase Labs's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of ProPhase Labs?
Shares of ProPhase Labs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ProPhase Labs's key executives?
ProPhase Labs's management team includes the following people:
- Mr. Ted William Karkus Chairman & Chief Executive Officer(age: 66, pay: $445,000)
- Ms. Monica Brady Chief Financial Officer(age: 48, pay: $213,080)
-
How many employees does ProPhase Labs have?
As Jul 2024, ProPhase Labs employs 113 workers, which is 12% less then previous quarter.
-
When ProPhase Labs went public?
ProPhase Labs, Inc. is publicly traded company for more then 31 years since IPO on 4 Apr 1994.
-
What is ProPhase Labs's official website?
The official website for ProPhase Labs is prophaselabs.com.
-
Where are ProPhase Labs's headquarters?
ProPhase Labs is headquartered at 711 Stewart Avenue, Garden City, NY.
-
How can i contact ProPhase Labs?
ProPhase Labs's mailing address is 711 Stewart Avenue, Garden City, NY and company can be reached via phone at 215 345 0919.
ProPhase Labs company profile:
ProPhase Labs, Inc.
prophaselabs.comExchange:
NASDAQ
Full time employees:
113
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
711 Stewart Avenue
Garden City, NY 11530
Garden City, NY 11530
CIK: 0000868278
ISIN: US74345W1080
CUSIP: 74345W108
